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Abstract 
The synthesis and characterization of a new class of DTPA bisamide-linked glycoconjugates of 
different sugars (lactose, Lac, and galactose, Gal) and valencies (di and tetra) and their Ln(III) 
complexes is reported. The 1H NMR spectra of the Sm(III) and Eu(III) complexes of 
DTPAGal2, DTPAGal4, and DTPALac2 obtained between 7 and 80 ºC, indicate that most (if 
not all) of the four possible diastereoisomeric pairs of structures, resulting from the chirality of 
the three bound DTPA nitrogen atoms, are present in solution, with different relative 
populations. The dynamic effects of racemization of the central nitrogen on the NMR spectra 
show that this process is in fast exchange at 60 ºC for the Sm(III) complexes and in slow 
exchange at 7 ºC for the Eu(III) complexes. The in vitro r1 nuclear magnetic relaxation 
dispersion (NMRD) of the water protons of the Gd(III)-DTPA bis-amide glycoconjugate 
containing two lactosyl moieties, Gd(III)-DTPALac2, was studied, yielding the molecular 
parameters that govern its relaxivity. Its r1 value, at 25 oC and 20 MHz,  is 13% higher than 
that reported for Gd(III) chelates of lower molecular weight DTPA-bisamides, such as DTPA-
BMA, consistent with a five times longer τR value. The water exchange rate, kex, and the 
electron spin relaxation parameters of the Gd(III)-DTPALac2 complex are within the usual 
range for similar Gd(III)-DTPA bisamide chelates.  
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Introduction 
Magnetic resonance imaging (MRI) is one of the fastest growing techniques in medical 
diagnosis, due to the excellent spacial resolution and contrast, in particular for soft tissues. The 
image contrast is based mainly on the differences of water proton longitudinal (1/T1) and 
transversal (1/T2) relaxation rates in different tissues. This contrast can be enhanced with the 
administration, prior to the scan, of paramagnetic contrast agents (CAs), usually Gd(III) (4f 7) 
complexes,[1,2] which accelerate the proton relaxation processes in the surrounding water 
through dipolar interactions between the unpaired electron spin of the metal ion and the proton 
nuclei of the water molecules. The Gd(III) chelate of DTPA (DTPA = 3,6,9-
tris(carboxymethyl)-3,6,9-triazaundecan-1,11-dioic acid)), [Gd(DTPA)(H2O)]2-, was the first 
contrast agent (CA) used for human MRI, under the name of Magnevist®.[3]  Its success 
stimulated further studies on modifications of its structure, leading amongst others to the 
neutral derivative [Gd(DTPA-BMA)(H2O)] (Omniscan®) (DTPA-BMA = diethylenetriamine-
pentaacetic acid-N,N”-bismethylamide), BMA= bismethylamide), in which two carboxylates 
were converted into amide functions. [4] These, as well as other hydrophilic linear or 
macrocyclic Gd(III) chelates of similar dimensions and simplicity, once injected, rapidly 
diffuse from the intravascular space into the interstitial space, but do not enter the intracellular 
space. Their rapid renal elimination produces a rapid decrease in tissue Gd concentration. [5]  
Although much used, eg. in neuro-pathological conditions, which are often associated with 
disruption of the blood brain barrier (BBB) or altered capillary permeability, these extracellular 
fluid (ECF) CAs also have inherent disadvantages due to their lack of biospecificity, low 
relaxivities and little uptake elsewhere in the body. Their rapid diffusion from the vasculature 
limits their uses as blood pool agents, eg. in estimates of blood flow and perfusion. For such 
applications, several formulations of DTPA conjugates have been tested, both through covalent 
binding of the Gd(III) chelate to suitable macromolecules (albumin,[6] dextran [7], polylysine [8], 
dendrimers [9]) or non-covalent binding to HSA (human serum albumin) [10], eg. of the Gd-
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DTPA derivative MS-325.[11] The search for new ligands with high tissue and/or organ 
specificity started with hepatobiliary CAs, eg. Gd(III) chelates which are hepatocyte-specific 
and are excreted through the hepatobiliary system.  Amongst these are Gd(III) chelates of 
DTPA-derived ligands bearing various lipophilic substituent groups which promote specific 
carrier-mediated uptake into the hepatocytes, such as benzyloxymethyl in 
[Gd(BOPTA)(H2O)]2- (BOPTA = 4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11 
-triazatridecan-13-oic acid) [12] and ethoxybenzyl in [Gd(EOB-DPTA)(H2O)]2- (EOB-DTPA = 
(S)-N-[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-N-[2-[bis(carboxy 
methyl)amino]ethyl]glycine).[13] Liposomes can also be efficient carriers to deliver Gd(III)-
based CAs to the liver and spleen and hence enhance their MRI image contrast, eg. the 
amphiphilic Gd(DTPA)-stearylamide was incorporated into the phospholipid lamella of egg 
lecitin and cholesterol liposomes.[14]  
The hepatocyte cells on liver express a tissue specific lectin (hepatic lectin) that recognizes 
terminal β-galactosyl residues on desialylated glycoproteins - the asialoglycoprotein receptor 
(ASGPR).[15] Liver targeting has been successfully achieved through conjugation of 
pharmaceutical agents to galactose/lactose.[16] Moreover, a multivalence effect has been 
demonstrated on the liver uptake of glycoconjugates (tetra>tri>di>mono).[17] Several agents,  
relying on macromolecular bioconjugates and on polymer scaffolds, have been described for 
hepatic imaging through the targeting of the ASGPR.[18-25] These agents are inherently 
polydisperse and ill characterised which constitutes a  drawback.     
In a previous paper, we reported the synthesis and physico-chemical characterization of a new 
class of multivalent glycoconjugates, Ln(III) chelates of the tetraazatetracarboxylate chelator  
DOTA conjugated to glycodendrimeric moieties (DOTA = 1,4,7,10-tetrakis(carboxymethyl)-
1,4,7,10-tetraazacyclododecane).[26] Previous to our work, only a class of low molecular weight 
and  well characterised galacto/mannopyranosyl conjugates of  DOTA-like chelators has been 
described for potential MRI and scintigraphic applications.[27] These monovalent Gd(III)-
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glycoconjugates are responsive contrast agents activated by galactosidase/mannosidase-
mediated hydrolysis.[28] In the present paper we report the synthesis and characterization of 
(thio)glycoconjugates of the linear chelator DTPA, namely the DTPA bisamides 1 and 2 with 
different terminal sugar residues: galactose (Gal) nd lactose (Lac), and different  valences (2 
and 4) (Figure 1). The thioglycosides are galactosidase-resistant ligands, probing a 
conformational space and displaying biological activities, very similar to that of their O-linked 
natural counterparts, ensuring thus an increased metabolic stability in vivo.[29] The physico-
chemical characterization of some of their Ln(III) complexes in aqueous solution by 1H NMR 
and water 1H NMRD studies is also described. The proton relaxivity of the Gd(III) chelates 
describes the efficiency of the magnetic dipolar coupling between the water proton nuclei and 
the paramagnetic metal ion, therefore it is a direct measure of the efficacy of the chelate as a 
CA.  
 
Results and Discussion 
Synthesis of the ligands: The synthesis of the DTPA-bisamies 1 and 2 (Figure 1) was 
undertaken through a well established route consisting on the derivatisation of the 
commercially available DTPA bisanhydride with amine-functionalised blocks. Two different 
types of amine-functionalised sugar blocks were prepared: a monovalent block 5 (Scheme1) 
and a divalent glycodendrimer block 9 (Scheme 2).[26,31] The standard DCC/HOBT coupling 
procedure revealed successful for preparing the fully protected amino-functionalised sugar 
blocks. These compounds were deprotected with TFA/CH2Cl2 to afford the terminal amines 6 
and 10 as their TFA salts.  
 In order to ensure the formation of the required bisamides, the amino-functionalised blocks 6 
and 10 were used in a slight excess, over two molar equivalents in relation to the DTPA 
bisanhydride block (Scheme 3). The intermediate sugar-protected bisamides were carried 
through and deprotected with KOMe to give the final compounds 1 and 2 in reasonable yields. 
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NMR studies of the Ln(III)-glycoconjugates: The 1H NMR spectra of the 1:1 diamagnetic 
(La(III)) and paramagnetic (Sm(III) and Eu(III)) complexes with the ligands DTPAGal2, 
DTPALac2  and DTPAGal4 were obtained in D2O, pH 7.5 as a function of temperature (7, 25, 
40, 60 and 80 ºC) (see Figure 2 for some typical spectra). The spectra of the La(III) complexes 
are identical to those of the corresponding free ligand at the same pH, except for the protons of 
the DTPA moiety, which, as a result of ion coordination, give more complex resonances: 
multiplets at 2.92, 2.78, 2.68 and 2.45 ppm for the backbone NCH2CH2N protons, and a series 
of partially overlapping AB patterns in the 3.2-3.5 ppm region for the CH2 protons of the 
acetate and amide arms, quite similar to what has been described for [La(DTPA)]2- and other 
La(DTPA-bisamides). [32-36] For the Sm(III) and Eu(III) complexes, the protons of the sugar 
moieties and the ones at the bridging arms further away from the DTPA moiety are hardly 
perturbed by the paramagnetic centre, with very small broadenings and paramagnetic shifts 
smaller than 0.05 ppm, due to the r-6 and  r-3 dependency, respectively, of the dominant dipolar 
contributions to the paramagnetic relaxation and shift induced by the Ln(III) ion, where r is the 
Ln(III)-proton distance in the complex.[36] However, the side chain protons closest to the DTPA 
amide moiety (eg. CH2(f) and CH2(g)) are increasingly shifted and broadened, in particular the 
CH2 resonances of the DTPA moiety, although these strongly shifted resonances are difficult to 
assign. However, their features show some similarities with the corresponding paramagnetic 
complexes of the parent DTPA and some DTPA-bisamide ligands .[36-42]  
For the Sm(III) complexes, eg. Sm(III)-DTPAGal2, the strongly shifted resonances are very 
broad at 25 ºC but become sharper as temperature increases. At 60 ºC some of these resonances 
are seen in the diamagnetic region of the spectrum (3.32, 2.22, 2.10, 1.69, 0.68 ppm), but seven 
distinct strongly shifted resonances appear at the low frequency + 0.1 ppm to –1.4 ppm region 
(0.06, -0.29, - 0.52, - 0.82, - 0.88, -0.98, - 1.39 ppm) (Fig. 2B). In contrast, in the case of the 
Eu(III) complexes, eg. Eu(III)-DTPAGal2, the strongly shifted resonances are quite sharp at 
low temperature (7 ºC, see Fig. 2C):  five more intense (33.40, 29.48, 27.41, 22.92, 16.75 ppm) 
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and five less intense (30.90, 38.05, 26.80, 24.38, 20.53 ppm) resonances are observed in the 
high frequency +35 ppm to +15 ppm region, about eight in the +10 ppm to + 5 ppm region and 
about twenty in the – 3 ppm to – 18 ppm region. These resonances broaden completely as the 
temperature increases to 25 ºC, but at 60 ºC some sharp, but somewhat less shifted resonances 
start to reappear, eg. at + 6.2, + 3.2, + 2.2, + 0.9, -0.1, -4.5, -8.5 and –10.2 ppm (data not 
shown). Comparison with 1H NMR spectra of corresponding DTPA complexes [33,39] suggests 
that the strongly shifted resonances at low frequencies for the Sm(III) complex and at high 
frequencies for the Eu(III) complex correspond to two CH2 protons of the DTPA 
ethylenediamine backbone, which have the largest dipolar induced shifts due to their very large 
and positive axial geometric factor G = (3 cos2θ - 1)/r3,[39]  where θ is the angle between the 
Ln(III)-proton vector and the main symmetry axis of the magnetic susceptibility of the 
complex. [36]  
In Ln(III) complexes of DTPA-bis amides with non-chiral centers in the side chains, all three 
bound nitrogen atoms are chiral and four diastereoisomeric pairs of enantiomers are possible, 
leading to a maximum of eight NMR signals for each group of magnetically equivalent 
protons. [36,40] Two isomerization processes have been described in solution for this type of 
complexes. While the racemization of the terminal N atoms, which involves decoordination-
inversion-coordination of the N atoms and the neighbouring acetate groups, has a high energy 
barrier, a lower energy process involves racemization of the central nitrogen, via 
interconversion between the two possible conformations of the ethylene bridges, which results 
in the magnetic averaging of the two halves of the complex around the central glycinate group 
of DTPA, reducing by half the number of observed resonances. [36,40] This is the dynamic 
process observed in the complexes studied here, which is in fast exchange at 60 ºC for the 
Sm(III) complexes and in slow exchange at 7 ºC for the Eu(III), due to the much larger dipolar 
shifts induced by Eu(III) relative to Sm(III).   The minimum of seven low frequency shifted 
resonances, observed for the Sm(III) complex at high temperature (Fig. 2B), resulting from two 
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ethylenic protons, indicates that most (if not all) of the four possible isomers are present in 
solution, with different relative populations. This is confirmed by the observation that the same 
two ethylenic protons give a minimum of ten (out of a maximum of sixteen) high frequency 
shifted resonances in the Eu(III) complex at high temperature (Fig. 2C). The Ln(III) complexes 
of other DTPA-bis amides, such as DTPA-BPA (BPA = bispropylamide) and DTPA-
BENGALAA (BENGALAA = N,N”-bis[N-(aza-D-galacto-5,6,7,8,9-pentahydroxynonyl)carba 
moylmethyl]amide) [35,41] have shown the presence of the four diastereoisomeric pairs, while 
for bisamides containing long (C14 to C18) aliphatic chains only two pairs have been detected 
in solution. [42]   
Water Proton Relaxation (NMRD) studies of Gd(III)-DTPALac2: The efficiency of a 
contrast agent is given by its proton relaxivity, defined as the paramagnetic enhancement of the 
longitudinal water proton relaxation rate referred to 1 mM concentration (r1, in s-1 mM-1). 
Proton relaxivity has contributions from interactions of the Gd(III) ion with the inner sphere 
water protons (inner sphere relaxivity) as well as with the bulk water protons (outer sphere 
relaxivity). The inner sphere term is determined by the exchange rate of the inner sphere water 
protons (usually equal to the water exchange rate, kex), the rotational correlation time of the 
complex (τR), and the longitudinal and transverse electronic relaxation rates of the Gd(III) 
(1/T1e and 1/T2e). The outer sphere contribution to the overall proton relaxivity depends on the 
electron spin relaxation rates and the diffusion coefficient for the diffusion of a water proton 
away from a Gd(III) chelate (see Appendix). [43] 
The water proton longitudinal relaxivity of the Gd(III)-DTPALac2 chelate was measured in 
aqueous solution at 25 and 60 °C at proton Larmor frequencies between 0.2 and 20 MHz. The 
NMRD profiles obtained (Figure 3) are typical of low molecular weight Gd(III) chelates. They 
were fitted to the usual Solomon-Bloembergen-Morgan theory that relates the paramagnetic 
relaxation rates to the microscopic parameters of the Gd(III) chelates (see equations in 
Supporting Information). In the analysis of the NMRD profiles we fixed the water exchange 
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rate and its activation enthalpy to values that were previously determined for similar DTPA-
bisamide complexes (kex298 = 0.40×106 s-1 and ∆H‡ = 40.0 kJ mol-1).[43] The diffusion 
coefficient and its activation energy were also fixed to common values (DGdH298 = 24×10-10 m2 
s-1; EDGdH = 20 kJ mol-1), as these two parameters are not much dependent on the nature of low 
molecular weight complexes.[43,44] Thus, in the analysis of the proton relaxivities we fitted the 
rotational correlation time, τR, its activation energy, ER, and the parameters describing the 
electron spin relaxation, i.e. the trace of the square of the transient zero-field-splitting (ZFS) 
tensor, ∆2, and the correlation time for the modulation of the ZFS, τv. The parameters obtained 
for the Gd(III)-DTPALac2 conjugate are presented in Table 1 and compared with those 
available for other relevant small Gd(III) complexes. The fits of the NMRD profiles obtained 
are shown in Figure 3.  
The relaxivity of Gd(III)-DTPALac2 (MW = 1569) at 25 oC and 20 MHz is 5.72 mM-1s-1, 
corresponding to an increase of 13 % compared to that for the commercial contrast agent 
Gd(III)-DTPA-BMA, which is a lower molecular weight DTPA-bisamide complex (MW = 
574).[44] This relaxivity difference is consistent with the five-fold increase in the rotational 
correlation time, as it is τR that dominates the high-field NMRD values. Another DTPA-
bisamide chelate, the Gd(III)-DTPA-BENGALAA, with an intermediate molecular weight 
(MW = 963), also has an intermediate τR value.[41] The temperature dependence of the NMRD 
profiles clearly shows that the proton relaxivity of these small molecular weight chelates is 
limited by fast rotation: proton relaxivities increase when the temperature decreases, thus the 
rotation slows down. The parameters obtained for the electron spin relaxation of the Gd(III) 
complex are also within the usual range for similar Gd(III)-DTPA bisamide chelates. Although 
the simplified model of electron spin relaxation used here is not fully adequate to describe 
Gd(III) chelates,[45] the application of the novel theories requires EPR data in a large field 
range which was beyond the scope of the present study. 
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Experimental Section 
Materials and equipment. Chemicals were purchased from Sigma-Aldrich and used without 
further purification. Solvents used were of reagent grade and purified by usual methods. 
Reactions were monitored by TLC on Kieselgel 60 F254 (Merck) on aluminium support. 
Detection was by examination under UV light (254 nm), by adsorption of iodine vapour and by 
charring with 10% sulphuric acid in ethanol. Flash chromatography was performed on 
Kieselgel 60 (Merck, mesh 230-400). The relevant fractions from flash chromatography were 
pooled and concentrated under reduced pressure, at temperature below 40 oC. FAB mass 
spectra (positive mode) were recorded using a VG Autospec mass spectrometer with 3-
nitrobenzyl alcohol (NBA) as matrix. Electrospray ionization (ESI) mass spectra were obtained 
for compounds with molecular weight above 2000. 1H NMR (1D and 2D) and 13C NMR 
spectra were run on a Varian Unity Plus 300 NMR spectrometer, operating at 299.938 MHz 
and 75.428 MHz, for 1H and 13C, respectively. Chemical shifts (δ) are given in ppm relative to 
the CDCl3 solvent (1H, δ 7.27; 13C 77.36) as internal standard. For 1H and 13C NMR spectra 
recorded in D2O, chemical shifts (δ) are given in ppm, respectively, relative to TSP as internal 
reference (1H, δ 0.0) and tert-butanol as external reference (13C, CH3 δ 30.29). 13C NMR 
spectra were proton broad-band decoupled using a GARP-1 modulated decoupling scheme. 
Assignments of the 1H and 13C NMR spectra were aided by two-dimensional gradient based 
double quantum filtered shift correlated spectra (DQF-COSY) and heteronuclear multiple 
quantum correlated spectra (HMQC). The pD of the D2O solutions was adjusted with DCl or 
CO2-free NaOD and converted to pH values using the isotopic correction pH = pD - 0.4. The 
pD values were measured on a HANNA pH-meter with a HI1310 combined electrode 
(HANNA instruments, Italy).  
The 1/T1 nuclear magnetic relaxation dispersion (NMRD) profiles of the water protons at 25 
and 60 oC were obtained on a Spinmaster FFC fast cycling NMR relaxometer (Stelar), covering 
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a continuum of magnetic fields from 5x10-4 to 0.47 T (corresponding to a proton Larmor 
frequency range of 0.022-20 MHz). The Gd(III) concentration was verified by ICP 
measurement (Perkin-Elmer Instruments, Optim 2000 DV). 
Synthesis and characterisation  
Synthesis of fully protected hexanediamine-functionalised monovalent thioglycosides (5a, 
and 5b). Typical procedure illustrated for (5a): A solution of peracetylated 
(galactosylthio)propionic acid 3a29a (0.375 g, 0.859 mmol), 1,6-hexanediamine monoBoc (4) 
(0.169 g, 0.781 mmol) and HBT (1-hydroxybenzotriazol) (0.140 g, 0.940 mmol) in 
dichloromethane (10 cm3) was ice-cooled. To this solution was added drop wise a solution 
DCC (dicyclohexylcarbodiimide) (0.194 g, 9.40 mmol) in dichloromethane (5 cm3). After 15 
minutes the reaction mixture was removed from the ice bath and allowed to reach room 
temperature. The reaction mixture was further stirred at room temperature overnight. The DCU 
(dicyclohexylurea) precipitate was removed by filtration and washed with dichloromethane. 
The filtrate was concentrated under reduced pressure to give tick syrup. This material was 
taken into ethyl acetate (100 cm3) and sequentially washed with KHSO4 (aq. Sol. 1 M.; 3 x 50 
cm3), NaHCO3 (sat. sol.; 3 x 50 cm3) and brine (50 cm3). The organic phase was concentrated 
under reduced pressure to give a white foam. Purification by dry flash chromatography 
(CH2Cl2 /MeOH; 100% CH2Cl2 -> 50% MeOH) afforded the title compound as a white foam 
(0.480 g, 97 % yield). 1H, δ (300 MHz, CDCl3) 1.34 (4H, m, NH(CH2)2(CH2)2(CH2)2NH), 1.43 
(9H, s, tertBu), 1.50 (4H, m, NHCH2CH2(CH2)2CH2CH2NH), 1.99, 2.05, 2.06 and 2.16 (12H, s, 
4xOAc), 2.50 (2H, m, SCH2CH2), 2.88-3.06 (2H, m, SCH2), 3.09 (2H, m, 
NH(CH2)5CH2NHBoc), 3.24 (2H, m, NHCH2(CH2)5NHBoc), 3.48 (1H, m(br)), 3.95 (1H, td, 
J= 7.2, 5.7 and 0.9 Hz, H-5), 4.11 (1H, dd, J= 11.2 and 5.7 Hz, H-6a), 4.19 (1H, dd, J= 11.2 
and 7.2 Hz, H-6b), 4.54 (1H, d, J= 9.9 Hz, H-1), 5.04 (1H, dd, J= 10.2 and 3.3 Hz, H-3), 5.23 
(1H, appt, J= 9.9 Hz, H-2), 5.43 (1H, dd, J= 3.3 and 0.9 Hz, H-4), 5.98 (1H, t(br), NH); HRMS 
(FAB+, NBA) Calc. for C28H47N2O12S  (M+H)+ 635.2844. Found 635.2856.  
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(5b): Starting from peracetylated (lactosylthio)propionic acid 3b29a (1.70 g, 2.35 mmol) and 
1,6-hexanediamine monoBoc (4) (0.507 g, 2.35 mmol), the title compound (5b) was obtained 
as a white foam (2.01 g, 93% ). 1H, δ (300 MHz, CDCl3) 1.33 (4H, m, 
NH(CH2)2(CH2)2(CH2)2NH), 1.42 (9H, s, tertBu), 1.70 (4H, m, NHCH2CH2(CH2)2CH2CH2NH), 
1.97, 2.04, 2.05, 2.07, 2.13 and 2.16 (21H, s, 7xOAc), 2.46 (2H, t, J= 6.6 Hz, SCH2CH2), 2.81 
(1H, m, SCHaHb), 3.03 (1H, m, SCHaHb), 3.08 (2H, m, NH(CH2)5CH2NHBoc), 3.21 (2H, m, 
NHCH2(CH2)5NHBoc), 3.45 (1H, m) 3.59 (1H, m, H-5), 3.78 (1H, appt, J= 9.6 Hz, H-4), 3.89 
(1H, appt, J=7.0 Hz, H-5´), 4.03-4.16 (3H, m), 4.28 (1H, m), 4.52 (1H, d, J= 7.8 Hz, H-1´), 
4.65 (1H, d, J= 10.5 Hz, H-1), 4.90 (1H, appt, J= 9.6 Hz, H-2), 4.96 (1H, dd, J= 10.2 and 3.3 
Hz, H-3´), 5.09 (1H, dd, J= 10.5 and 7.8 Hz, H-2´), 5.19 (1H, appt J= 9.3 Hz, H-3), 5.34 (1H, 
d, J= 2.4 Hz, H-4´), 6.30 (2H, t(br), NHC(O)); m/z (FAB+, NBA) 923 (M+H)+, 3); HRMS 
(FAB+, NBA) Calc. for C40H63N2O20S  (M+H)+ 923.3695. Found 923.3683.  
Synthesis of fully protected amino-functionalised divalent (9)  
A solution of divalent thiogalactoside 726 (0.968 g, 0.895 mmol) was stirred overnight with 
CH2Cl2/TFA (3/1, 10 cm3). The solvent was removed under reduced pressure to give a light 
yellow foam, which was redissolved in dichloromethane (DCM) (10 cm3) and the solvent was 
removed under reduced pressure. This procedure was repeated several times and the material 
was further dried under vacuum to give the carboxylic acid deprotected compound (8) as a 
thick light yellow foam. 1H NMR analysis revealed the disappearance of the signal at δ 1.4 
assigned to the tert-butyl group. No further purification or characterisation was carried on this 
material. All the material obtained (we assumed a 100 % yield on the deprotection reaction) 
was dissolved in ice-cooled DCM (10 cm3) and titrated (pH paper) to pH 9-10 with DIPEA 
(diisopropylethylamine). To this solution was added a solution of 1,6-hexadiamine monoBoc 
(4) (0.230 g, 1.07 mmol) in dichloromethane (5 cm3)  and HBT (0.140 g, 0.940 mmol). To this 
solution was added drop wise a solution of DCC (0.230 g, 1.10 mmol) in dichloromethane (5 
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cm3). After 15 minutes the reaction mixture was removed from the ice bath and allowed to 
reach room temperature. The reaction mixture was further stirred at room temperature 
overnight. The DCU precipitate was removed by filtration and washed with dichloromethane. 
The filtrate was concentrated under reduced pressure to give tick syrup. This material was 
taken into ethyl acetate (150 cm3) and sequentially washed with, NaHCO3 (sat. sol.; 3 x 100 
cm3) and brine (100 cm3). The organic phase was concentrated under reduced pressure to give 
a light yellow foam. Purification by dry flash chromatography (CH2Cl2 /MeOH; 100% CH2Cl2 
-> 50% MeOH) afforded the title compound as a white foam (1.01 g, 92 % yield). 1H, δ (300 
MHz, CDCl3) 1.32 (4H, m, NH(CH2)2(CH2)2(CH2)2NH), 1.43 (9H, s, tertBu), 1.51 (4H, m, 
NHCH2CH2(CH2)2CH2CH2NH), 1.72 (4H, m, NCH2CH2) 1.99, 2.05, 2.06 and 2.16 (24H, s, 
8xOAc), 2.52 (8H, m, overllaping signals from  SCH2CH2 and NCH2), 2.88-3.14 (8H, m, 
overllaping signals from  SCH2, NCH2C(O) (singulet at 3.02) and  NH(CH2)5CH2NHBoc), 
3.29 (6H, m, NCH2CH2CH2) and NHCH2(CH2)5NHBoc), 3.40-3.56  (1H, m), 3.96 (2H, td, J= 
6.4 and 0.9 Hz, H-5), 4.09 (2H, dd, J= 11.4 and 6.3 Hz, H-6a), 4.20 (2H, dd, J= 11.2 and 6.4 
Hz, H-6b), 4.56 (2H, d, J= 10.2, H-1), 4.74 (1H, t(br), NH), 5.05 (2H, dd, J= 10.0 and 3.3 Hz, 
H-3), 5.25 (2H, appt, J= 9.9 Hz, H-2), 5.44 (2H, dd, J= 3.3 and 0.9 Hz, H-4), 6.74 (2H, t(br), 
NH), 7.10 (2H, t(br); m/z (FAB+, NBA) 1223 (M-H)+, 100); HRMS (FAB+, NBA) Calc. for 
C53H86N5O23S2  (M+H)+ 1224.5155. Found 1224.5119.  
 
Synthesis of DTPA-glycoconjugate bisamides 1 and 2 
Typical procedure illustrated for DTPAGal2 (1a): A solution of fully protected amino-
functionalised monovalent thiogalactoside 5a (0.618 g, 0.973 mmol) was stirred overnight with 
CH2Cl2/TFA (3/1, 10 cm3). The solvent was removed under reduced pressure to give a light 
yellow foam, which was redissolved in DCM (10 cm3) and the solvent was removed under 
reduced pressure. This procedure was repeated several times and the material was further dried 
under vacuum to give a thick light yellow foam (6a). 1H NMR analysis revealed the 
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disappearance of the signal at δ 1.47 assigned to the tert-butyl group. No further purification or 
characterisation was carried on this material. All the material obtained (we assumed a 100 % 
yield on the deprotection reaction) was dissolved in ice-cooled DCM (5 cm3) and titrated (pH 
paper) to pH 9-10 with DIPEA. This solution was added to a solution of DTPA-bis anhydride 
(0.158 g, 0.442 mmol) in DMF (40 cm3) and pyridine (1 cm3). The reaction mixture was stirred 
at room temperature overnight and concentrated at reduced pressure to give a colourless oil. 
This material was carried through without further purification or characterisation. The residue 
was redissolved in a mixture ethanol (10 cm3) and KOH (aq. sol. 1M, 10 cm3) and stirred at 
room temperature overnight. The reaction mixture was adjusted to pH~1 with Amberlist 15. 
The resin was transferred into a column, thoroughly washed with water and eluted with aq. 
NH3 0.5 M. The relevant fractions were pooled and concentrated under reduced pressure 
(temperature below 40 0C ) to give the fully deprotected glycoconjugate as a off white solid 
(0.342 g, 71% yield over two steps). 1H, δ (300 MHz, D2O, pH 7.0): 4.48 (2H, d, J = 9.0 Hz, 
H-1), 3.54 (2H, app t, J = 9.0 Hz, H-2), 3.64 (2H, dd, J = 9.0 and 3.3 Hz, H-3), 3.70 (2H, m, H-
4), 3.96 (2H, app d, J = 3.3 Hz, H-5), 3.73 (4H, m, H-6a + H-6b), 1.32 (8H, m, 2 x 
NH(CH2)2(CH2)2(CH2)2NH), 1.51 (8H, m, 2 x NHCH2CH2(CH2)2CH2CH2NH), 3.20 (8H, m, 2 
x NHCH2(CH2)4CH2NH), 2.60 (4H, m, SCH2CH2), 2.95-3.01 (4H, m, SCH2),  3.24 (4H, s, 
DTPA amide NCH2C(O)), 3.76 (2H, s, DTPA central acetate NCH2CO2-), 3.40 (4H, s, DTPA 
terminal acetate NCH2CO2-), 3.34, 3.08 (8H, two m, DTPA skeleton NCH2); 13C, δ (75.6 ΜΗz, 
D2O): 86.18 (C-1), 69.67 (C-2), 74.05 (C-3), 79.07 (C-4), 68.94 (C-5), 61.30 (C-6), 25.90, 
25.83 (NH(CH2)2(CH2)2(CH2)2NH), 28.29, 28.42 (NHCH2CH2(CH2)2CH2CH2NH), 39.23, 
39.54  (NHCH2(CH2)4CH2NH), 26.49 (SCH2), 36.57 (SCH2CH2), 58.86 (DTPA amide 
NCH2C(O)), 54.58 (DTPA central acetate NCH2CO2-), 58.95 (DTPA terminal acetate 
NCH2CO2-),  50.59, 52.79 (DTPA skeleton NCH2), 170.77, 173.02, 174.28, 178.40 (DTPA 
acetate NCH2CO2- and amide NCH2C(O), other CH2C(O)NH); m/z (FAB+, NBA) 1091 
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(M+H+, 23); HRMS (FAB+, NBA) Calc. for C44H80N7O20S2  (M+H)+ 1090.4899. Found 1090. 
4859.  
DTPALac2 - (1b): Fully protected monovalent thiolactoside (5b) (0.997 g, 1.08 mmol) was 
deprotected as described for compound (1a). Reaction with DTPA-bis anhydride (0.183 g, 
0.512 mmol), followed by deprotection and purification afforded glycoconjugate 1b as a off 
white solid (0.345 g, 48% yield over two steps). 1H, δ (300 MHz, D2O, pH 7.0): 4.46 (2H, d, J 
= 7.8 Hz, H-1), 3.54 (2H, dd, J = 10.2 and 7.8 Hz, H-2), 3.63 (2H, dd, J = 10.2 and 3.3 Hz, H-
3), 3.66 (2H, dd, H-4), 3.94 (2H, app d, J = 3.3 Hz, H-5), 3.70 (4H, m, H-6a + H-6b), 4.58 (2H, 
d, J= 10.2 Hz, H-1’), 3.36 (2H, app t, H-2’), 3.64 (2H, app t, H-3’), 3.68 (2H, dd, H-4’), 3.99 
(2H, dd, H-5’), 3.72 (4H, m, H-6a’ + H-6b’) (Gal unit: -H-1-H-6b; Gluc unit: -H-1’-H-6b’), 1.32 
(8H, m, 2 x NH(CH2)2(CH2)2(CH2)2NH), 1.52 (8H, m, 2 x NHCH2CH2(CH2)2CH2CH2NH), 
3.20 (8H, m, 2 x NHCH2(CH2)4CH2NH), 2.61 (4H, m, SCH2CH2), 2.98-3.01 (4H, m, SCH2),  
3.23 (4H, s, DTPA amide NCH2C(O)), 3.76 (2H, s, DTPA central acetate NCH2CO2-), 3.38 
(4H, s, DTPA terminal acetate NCH2CO2-), 3.37, 3.08 (8H, two m, DTPA skeleton NCH2); 
13C, δ (75.6 ΜΗz, D2O):  103.08 (C-1), 71.15 (C-2), 78.42 (C-3), 72.71 (C-4), 60.49 (C-5), 
75.55 (C-6), 85.59 (C-1’), 72.11 (C-2’), 78.82 (C-3’), 75.92 (C-4’), 68.76 (C-5’), 61.22 (C-6’) 
(Gal unit: C-1-C-6; Gluc unit: C-1’-C-6’), 25.86, 25.94 (NH(CH2)2(CH2)2(CH2)2NH), 28.33, 
28.47 (NHCH2CH2(CH2)2CH2CH2NH), 39.26, 39.58 (NHCH2(CH2)4CH2NH), 26.45 (SCH2), 
36.61 (SCH2CH2), 58.86 (DTPA amide NCH2C(O)), 54.33 (DTPA central acetate NCH2CO2-), 
59.03, 59.11 (DTPA terminal acetate NCH2CO2-),  50.53, 52.88 (DTPA skeleton NCH2), 
170.60, 173.41, 174.24, 178.82 (DTPA acetate NCH2CO2- and amide NCH2C(O), other 
CH2C(O)NH) ); HRMS (ESI) Calc. for C56H100N7O30S2  (M+H)+ 1414.5950. Found 1414.5971. 
. 
DTPAGal4 – (2): Fully protected aminofunctionalised divalent thiogalactoside (9) (0.464 g, 
0.379 mmol) was deprotected as described for compound (1a). Reaction with DTPA-bis 
anhydride (0.064 g, 0.179 mmol), followed by deprotection and purification afforded 
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glycoconjugate 2 as an off white solid (0.240 g, 69% yield over two steps). 1H, δ (300 MHz, 
D2O, pH 7.0): 4.46 (4H, d, J = 9.0 Hz, H-1), 3.52 (4H, app t, J = 9.0 Hz, H-2), 3.64 (4H, dd, 
dd, J = 9.0 and 3.3 Hz, H-3), 3.68 (4H, m, H-4), 3.95 (4H, app d, J = 3.3 Hz, H-5), 3.71 (8H, 
m, H-6a + H-6b), 1.28 (8H, m, 2 x NH(CH2)2(CH2)2(CH2)2NH), 1.49 (8H, m, 2 x 
NHCH2CH2(CH2)2CH2CH2NH), 3.18 (8H, m, 2 x NHCH2(CH2)4CH2NH), 3.48  (4H, m, 
NCH2C(O)), 2.75 (8H, m, NCH2), 1.83 (8H, m, NCH2CH2), 3.20 (8H, m, NCH2CH2CH2), 2.59 
(8H, m, SCH2CH2), 2.97 (8H, m, SCH2),  3.20 (4H, s, DTPA amide NCH2C(O)), 3.71 (2H, s, 
DTPA central acetate NCH2CO2-), 3.33 (4H, s, DTPA terminal acetate NCH2CO2-), 3.34, 3.18 
(8H, two m, DTPA skeleton NCH2); 13C, δ (75.6 ΜΗz, D2O): 86.29 (C-1), 69.66 (C-2), 74.09 
(C-3), 79.08 (C-4), 68.95 (C-5), 61.41 (C-6), 25.33 (NH(CH2)2(CH2)2(CH2)2NH), 28.53 
(NHCH2CH2(CH2)2CH2CH2NH), 39.32, 39.18  (NHCH2(CH2)4CH2NH), 56.57 (NCH2C(O)), 
52.51 (NCH2), 25.38 (NCH2CH2), 37.11 (NCH2CH2CH2), 26.70 (SCH2), 36.52 (SCH2CH2), 
59.20 (DTPA amide NCH2C(O)), 54.50 (DTPA central acetate NCH2CO2-), 59.11 (DTPA 
terminal acetate NCH2CO2-),  50.51, 52.89 (DTPA skeleton NCH2), 170.51, 173.40, 174.48, 
178.85 (DTPA acetate NCH2CO2- and amide NCH2C(O)NH, other CH2C(O)NH); m/z (FAB+, 
NBA) 1932 (M+, 20), 1055 (100); HRMS (FAB+, NBA) Calc. for C78H142N13O34S4  (M+H)+ 
1932.8665. Found 1932.8576. 
Preparation of Ln(III)-glycoconjugates for NMR studies 
The Ln(III)-glycoconjugates were prepared by adding a slight excess (1.1 eq.) of LnCl3 
aqueous solution to an aqueous solution of the glycoconjugate. The pH of the solution was 
slowly adjusted to 5 with KOH (aq), stirred at 70 oC for eight hours and adjusted to pH 7 with 
KOH (aq). Any precipitate was filtered off. The solution was concentrated and purified by gel 
filtration with Sephadex G10, eluting with water. The relevant fractions were pooled and freeze 
dried to afford the Ln(III) complexes.  
Preparation of Gd(III)-DTPALac2 for NMRD measurements 
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Initially, the DTPALac2 conjugate was left to react with an excess of Gd(ClO4)3 stock solution 
and the excess of metal ion was backtitrated with Na2H2EDTA solution, allowing the 
calculation of the exact concentration of glycoconjugate. 
The Gd(III) chelate of DTPALac2 was prepared by adding an appropriate quantity of the 
glycoconjugate to aqueous solution of gadolinium perchlorate (3-5% glycoconjugate excess). 
The solution pH was slowly adjusted to 7 with KOH (aq). The Gd(III)-glycoconjugate solution 
was freeze-dried and diluted with 25 mM phosphate buffer (pH 7.4). The absence of free 
Gd(III) in the solution was verified by using xylenol orange indicator.[30] The Gd(III) 
concentration (4.63 mM) was verified by ICP measurement.  
 
Conclusions 
We have devised the synthesis of a new class of hydrophylic glycoconjugate DTPA-bisamides. 
Their dendrimeric architecture is especially suited for the variation of the valence of the 
glycoconjugates from a reduced number of building blocks in an interactive fashion. 
The Ln(III) ions in the chelates of these glyconjugates are nine coordinated, as expected  for 
DTPA bisamides, with one inner-sphere water molecule and eight positions occupied by three 
nitrogens and five oxygens of the DTPA moiety. In aqueous solution, these complexes display 
the four possible diastereoisomeric pairs, resulting from the chirality of the three bound DTPA 
nitrogen atoms, like the Ln(III) complexes of other DTPA-bisamides with smaller substituents, 
such as DTPA-BMA and DTPA-BENGALAA, [35,41] while bisamides containing long, micelle-
forming, aliphatic chains, only two pairs have been detected in solution, [42]  possibly stabilized 
by intermolecular interactions. 
The value found for the r1 relaxivity of Gd(III)-DTPALac2 at 25 oC and 20 MHz is 13% higher 
than that reported for Gd(III) chelates of lower molecular weight DTPA-bisamides, such as 
DTPA-BMA, consistent with a longer τR value. The τR value of these Gd(III) chelates is 
expected to increase linearly with molecular weight, as long as the internal mobility of the side 
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chains does not change significantly, leading to a proportional increase of the 20 MHz 
relaxivity. This result suggests that the relaxivity of the tetravalent Gd(III)-DTPAGal4 
glycoconjugate (MW= 2088) would be substantially higher. This finding, taken together with a 
potential to target the ASGPR (studies under way), makes these compounds promising for the 
design of medical imaging agents (MRI and gamma scintigraphy). 
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Table 1 - Parameters obtained from the analysis of the NMRD profiles for Gd(III)-DTPALac2 
in comparison with other Gd(III) complexes. 
 
 DTPA[44] DTPA-BMA[44] DTPA-BENGALAA[41] DTPALac2 DOTALac2[26] 
  (bisamide) (bisamide) (bisamide) (monoamide) 
kex298/ 106 s-1 3.3 0.45 0.22 0.40a  1.2a 
∆H‡ / kJ mol-1 51.6 47.6 42.5 40.0a 30.0a 
τrH298 / ps 58 66 265 332±10 306 
ERH / kJ mol-1 17.3 21.9 19.7 36.3±0.2 29.9 
τv298 / ps  25 25 16 10±2 33 
Ev / kJ mol-1 1.6 3.9 5.5 1a 1a 
∆2 / 1020 s-2 0.46 0.41 0.53 0.63±0.02 0.12 
 
a. Underlined parameters have been fixed in the fit.  
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Figure 1 - Structures of the DPTA-bisamides glycoconjugates (the labeling of the protons for 
spectral assignements is shown). 
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Figure 2A - 1H NMR spectrum of La(III)-DTPAGal2 glycoconjugate in D2O, pH 7.0, T = 25 
ºC.   
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Figure 2B - 1H NMR spectrum of Sm(III)-DTPAGal2 glycoconjugate in D2O, pH 7.0, T = 60 
ºC.   
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Figure 2C - 1H NMR spectrum of Eu(III)-DTPAGal2 glycoconjugate in D2O, pH 7.0, T = 7 ºC
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Figure 3 - Variable temperature NMRD profiles for Gd(III)-DTPALac2; T = 25 °C (triangles); 
and 60 °C (circles). The lines represent the least squares fit to the experimental data points as 
described in the text.  
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Scheme 1 : a) DCC/HBT, DCM; b) TFA/DCM (1/3).   
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Scheme 2 : a) TFA/DCM (1/3); b) i. DIPEA /DCM ii. DCC/HBT, DCM. 
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Scheme 3 : a) i. DIPEA/DCM ii. DMF / Py; b) i. KOH / EtOH ii. Amberlist 15, elution with 
NH3.  
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Supporting Information 
 
Table S1. Proton relaxivities of Gd(III)-DTPA-Lac2. 
 
Frequency
(MHz) 
25 °C  Frequency
(MHz) 
60 °C 
10.001 5.811 15.998 4.1
6.9516 6.175 10.853 4.123
4.8342 6.398 7.36 4.229
3.3593 7.080 4.9912 4.672
2.335 7.601 3.384 5.109
1.6231 7.540 2.296 5.843
1.1293 8.033 1.5569 5.993
0.78425 8.037 1.0565 6.301
0.54522 8.204 0.48561 6.311
0.379 8.281 0.32959 6.476
0.26382 8.347 0.22346 6.602
0.1833 8.551 0.15136 6.626
0.12722 8.644 0.10281 6.599
0.088466 8.656 0.069612 6.607
0.061485 8.682 0.047272 6.72
0.042866 8.526 0.032022 6.635
0.029663 8.581 0.021664 6.628
0.020774 8.681 0.014771 6.799
0.01433 8.578 0.010031 6.788
0.010031 8.734 20 4.011
12 5.823   
16 5.671   
20 5.722   
 
 
 
Equations for the determination of the relaxivity parameters 
 
NMRD. The measured proton relaxivities (normalized to 1 mM Gd(III) concentration) contain 
both inner and outer sphere contributions:  
r r r1 1is 1os= +                                                                (1) 
The inner sphere term is given by Equation (2), where q is the number of inner sphere water 
molecules.  
r
q
T1is 1m
H
m
= × × +
1
1000 5555
1
. τ                                    (2) 
The longitudinal relaxation rate of inner sphere protons, 1/T1mH is expressed: 
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Here rGdH is the effective distance between the Gd(III) electron spin and the water protons, ωI 
is the proton resonance frequency and τdiH is given by Equation (4), where τR is the rotational 
correlation time of the Gd(III)-Hwater vector:  
eRmd
1111
iiH T
++= τττ                i = 1 , 2                                                                    (4) 
The τR rotational correlation time is assumed to have simple exponential temperature 
dependence with an ER activation energy:  
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The electron spin relaxation rates, 1/T1e and 1/T2e for metal ions in solution with S > 1/2 are 
mainly governed by a transient zero-field-splitting mechanism (ZFS).[46] In Equations (6-7) ∆2 
is the trace of the square of the transient zero-field-splitting tensor, τv is the correlation time for 
the modulation of the ZFS with the activation energy Ev, and ωs is the electron spin Larmor 
frequency: 
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The outer sphere contribution is described by Equation (9), where NA is the Avogadro constant, 
and Jos is a spectral density function.  
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      j = 1, 2                                                                                                       (10) 
 
A value of 3.6 Å was used for aGdH. For the temperature dependence of the diffusion 
coefficient for the diffusion of a water proton away from a Gd(III) complex, DGdH, we assume 
a exponential temperature dependence, with an activation energy EDGdH:  
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